



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

December 2021





© 2022 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
687 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8515  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.bccfe.ca](http://www.bccfe.ca)  
Email: [info@bccfe.ca](mailto:info@bccfe.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





### TABLE OF CONTENTS

#### 1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

#### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2021 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

December 2021

N = 7477



Health Authority	Male	Female	All
FRASER	1469	444	1913
INTERIOR	448	106	554
NORTHERN	140	81	221
VANCOUVER COASTAL	3324	450	3774
VANCOUVER ISLAND	798	169	967
	<b>6179</b>	<b>1250</b>	<b>7429</b>
		<b>Unknown/not stated:</b>	<b>48</b>
		<b>Total:</b>	<b>7477</b>

Definitions:

**On antiretroviral therapy** defined as being on treatment in the current month


**Unknown/not stated** defined as being on treatment in the current month, and city of residence unknown

**Male & Female** refer to Sex at birth





### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (December 2016 - December 2021)




**Notes:**

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (December 2016 - December 2021)



**Notes:**


Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month








### 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (December 2016 - December 2021)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (December 2016 - December 2021)






### 1.6 Percent Distribution of Active Participants by CD4 Count (December 2016 - December 2021)






### 1.7 Percent Distribution of Inactive Participants by CD4 Count (December 2016 - December 2021)






### 1.8 Active and Inactive Participants (December 2016 - December 2021)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (December 2016 - December 2021)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (December 2016 - December 2021)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(December 2016 - December 2021)








### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (December 2016 - December 2021)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(December 2016 - December 2021)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (December 2016 - December 2021)






### 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(December 2016 - December 2021)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (December 2016 - December 2021)






**1.17 Distribution of Participants on Entry/Integrase Inhibitors  
at the time of first ARV Therapy by INGREDIENT  
(December 2016 - December 2021)**






1.18 Baseline CD4 for Antiretroviral First Starts  
(December 2016 - December 2021)






### 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (December 2016 - December 2021)








### 1.20 Cumulative Resistance Testing Results by Resistance Category (December 2016 - December 2021)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (December 2016 - December 2021)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2021  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	29	5	0	5	2	585	5	<40	4
1988	31	5	0	5	4	505	5	<40	3
1989	29	53	1	54	28	505	51	<40	3
1990	27	54	1	55	31	550	52	<40	3
1991	28	36	3	39	21	650	36	<40	3
1992	27	57	5	62	29	560	58	<40	3
1993	26	122	14	136	89	510	130	<40	3
1994	25	72	12	84	54	540	77	<40	3
1995	25	126	20	146	98	565	135	<40	3
1996	23	312	45	357	223	570	337	<40	3
1997	21	268	32	300	195	650	274	<40	3
1998	20	191	41	232	149	560	205	<40	3
1999	20	154	37	191	117	540	172	<40	3
2000	20	118	28	146	98	595	135	<40	3
2001	20	118	24	142	91	590	124	<40	3
2002	19	121	26	147	99	610	132	<40	3
2003	18	142	26	168	97	630	156	<40	3
2004	17	147	38	185	128	598	168	<40	3
2005	16	176	43	219	149	650	198	<40	3
2006	15	167	39	206	127	630	181	<40	3
2007	14	228	47	275	193	650	246	<40	3
2008	13	276	63	339	235	630	306	<40	3
2009	12	300	64	364	243	650	331	<40	3
2010	11	268	66	334	236	655	301	<40	3
2011	10	324	71	395	249	720	347	<40	3
2012	9	269	64	333	218	710	293	<40	3
2013	8	250	62	312	219	680	275	<40	3
2014	7	261	49	310	195	720	277	<40	3
2015	6	275	46	321	210	720	276	<40	3
2016	5	258	55	313	201	650	273	<40	3
2017	4	214	33	247	175	650	224	<40	3
2018	3	188	55	243	172	698	220	<40	3

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2021  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	2	231	43	274	201	670	255	<40	3
2020	2	188	54	242	176	700	217	<40	3
2021	1	223	43	266	207	566	250	<40	3
<b>Total:</b>		<b>6197</b>	<b>1250</b>	<b>7447</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2020	7358	774	2227	<40	1729	610
FEB-2020	7329	776	1882	<40	1417	620
MAR-2020	7387	768	1628	<40	1207	620
APR-2020	7408	770	767	<40	577	600
MAY-2020	7397	776	1186	<40	892	600
JUN-2020	7368	784	1558	<40	1148	620
JUL-2020	7333	794	1918	<40	1437	610
AUG-2020	7254	791	1848	<40	1332	630
SEP-2020	7233	784	1735	<40	1243	620
OCT-2020	7265	776	1782	<40	1309	630
NOV-2020	7340	763	1858	<40	1284	610
DEC-2020	7346	752	1542	<40	1085	630
JAN-2021	7384	746	1942	<40	1391	630
FEB-2021	7377	748	1787	<40	1273	630
MAR-2021	7432	743	2016	<40	1426	620
APR-2021	7417	746	1828	<40	1322	633
MAY-2021	7452	742	1868	<40	1304	630
JUN-2021	7456	738	1880	<40	1352	610
JUL-2021	7461	744	1820	<40	1343	640
AUG-2021	7471	740	1981	<40	1346	630
SEP-2021	7442	749	1762	<40	1234	630
OCT-2021	7439	755	1856	<40	1275	630
NOV-2021	7457	749	2020	<40	1340	630
DEC-2021	7477	757	1545	<40	986	630

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2020	635	185	70	354	46	435
FEB-2020	675	173	71	<40	58	480
MAR-2020	632	188	50	<40	32	415
APR-2020	611	204	28	116	22	555
MAY-2020	630	187	42	<50	30	490
JUN-2020	662	181	56	<40	46	480
JUL-2020	729	161	72	<40	56	625
AUG-2020	819	142	75	<40	65	470
SEP-2020	871	137	93	<40	71	610
OCT-2020	866	178	87	<40	75	570
NOV-2020	794	192	78	<40	63	510
DEC-2020	799	186	65	<40	55	420
JAN-2021	782	203	73	<40	56	525
FEB-2021	795	199	69	<40	56	510
MAR-2021	780	251	89	<40	70	630
APR-2021	813	258	73	<40	58	615
MAY-2021	792	276	73	<40	65	530
JUN-2021	791	272	65	57	48	535
JUL-2021	794	278	52	102	37	530
AUG-2021	800	273	53	<40	40	645
SEP-2021	845	230	65	<40	42	605
OCT-2021	846	245	78	<40	60	540
NOV-2021	830	270	79	<40	59	450
DEC-2021	806	271	46	<40	29	360

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2020	7328	635	10	12	183	155	18	13903
FEB-2020	7295	675	12	19	141	172	-33	13939
MAR-2020	7358	632	14	23	210	152	63	13975
APR-2020	7382	611	12	8	158	127	24	14000
MAY-2020	7375	630	10	15	130	135	-7	14025
JUN-2020	7345	662	9	9	125	149	-30	14042
JUL-2020	7308	729	15	12	160	189	-37	14074
AUG-2020	7222	819	18	11	168	240	-86	14094
SEP-2020	7193	871	19	8	229	241	-29	14115
OCT-2020	7225	866	20	13	222	176	32	14136
NOV-2020	7309	794	12	11	245	155	84	14162
DEC-2020	7323	799	10	13	205	191	14	14191
JAN-2021	7361	782	14	9	205	159	38	14211
FEB-2021	7353	795	15	13	186	190	-8	14235
MAR-2021	7407	780	15	24	203	156	54	14272
APR-2021	7393	813	13	9	165	172	-14	14297
MAY-2021	7421	792	14	14	177	143	28	14326
JUN-2021	7438	791	7	15	186	175	17	14352
JUL-2021	7439	794	9	12	170	168	1	14372
AUG-2021	7438	800	16	12	174	167	-1	14394
SEP-2021	7401	845	14	9	172	199	-37	14424
OCT-2021	7398	846	16	6	186	174	-3	14447
NOV-2021	7426	830	11	15	199	175	28	14473
DEC-2021	7447	806	19	6	205	171	21	14491

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2020	60	6758	484	56	<b>7358</b>	0.82%	91.85%	6.58%	0.76%	<b>100.00%</b>
FEB-2020	59	6735	477	58	<b>7329</b>	0.81%	91.90%	6.51%	0.79%	<b>100.00%</b>
MAR-2020	60	6790	487	50	<b>7387</b>	0.81%	91.92%	6.59%	0.68%	<b>100.00%</b>
APR-2020	61	6814	483	50	<b>7408</b>	0.82%	91.98%	6.52%	0.67%	<b>100.00%</b>
MAY-2020	60	6806	481	50	<b>7397</b>	0.81%	92.01%	6.50%	0.68%	<b>100.00%</b>
JUN-2020	59	6774	484	51	<b>7368</b>	0.80%	91.94%	6.57%	0.69%	<b>100.00%</b>
JUL-2020	61	6753	471	48	<b>7333</b>	0.83%	92.09%	6.42%	0.65%	<b>100.00%</b>
AUG-2020	70	6677	457	51	<b>7255</b>	0.96%	92.03%	6.30%	0.70%	<b>100.00%</b>
SEP-2020	85	6641	456	52	<b>7234</b>	1.18%	91.80%	6.30%	0.72%	<b>100.00%</b>
OCT-2020	107	6645	462	51	<b>7265</b>	1.47%	91.47%	6.36%	0.70%	<b>100.00%</b>
NOV-2020	162	6673	456	49	<b>7340</b>	2.21%	90.91%	6.21%	0.67%	<b>100.00%</b>
DEC-2020	180	6656	461	49	<b>7346</b>	2.45%	90.61%	6.28%	0.67%	<b>100.00%</b>
JAN-2021	205	6681	452	46	<b>7384</b>	2.78%	90.48%	6.12%	0.62%	<b>100.00%</b>
FEB-2021	226	6652	448	51	<b>7377</b>	3.06%	90.17%	6.07%	0.69%	<b>100.00%</b>
MAR-2021	249	6669	463	51	<b>7432</b>	3.35%	89.73%	6.23%	0.69%	<b>100.00%</b>
APR-2021	275	6644	454	44	<b>7417</b>	3.71%	89.58%	6.12%	0.59%	<b>100.00%</b>
MAY-2021	299	6640	465	48	<b>7452</b>	4.01%	89.10%	6.24%	0.64%	<b>100.00%</b>
JUN-2021	326	6613	471	46	<b>7456</b>	4.37%	88.69%	6.32%	0.62%	<b>100.00%</b>
JUL-2021	354	6591	470	46	<b>7461</b>	4.74%	88.34%	6.30%	0.62%	<b>100.00%</b>
AUG-2021	381	6576	472	42	<b>7471</b>	5.10%	88.02%	6.32%	0.56%	<b>100.00%</b>
SEP-2021	398	6534	463	47	<b>7442</b>	5.35%	87.80%	6.22%	0.63%	<b>100.00%</b>
OCT-2021	409	6522	462	46	<b>7439</b>	5.50%	87.67%	6.21%	0.62%	<b>100.00%</b>
NOV-2021	438	6517	459	43	<b>7457</b>	5.87%	87.39%	6.16%	0.58%	<b>100.00%</b>
DEC-2021	468	6505	459	45	<b>7477</b>	6.26%	87.00%	6.14%	0.60%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)







**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		stavudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine															
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All														
JAN-2020	2	8%	3402	47%	2	8%	3226	45%	0	0%	34	0%	0	0%	1	0%	9	38%	1024	14%	13	54%	2963	41%	22	92%	3763	52%
FEB-2020	3	8%	3351	47%	3	8%	3179	45%	0	0%	33	0%	0	0%	1	0%	16	44%	1169	16%	17	47%	2825	40%	33	92%	3781	53%
MAR-2020	5	14%	3325	46%	5	14%	3160	44%	1	3%	34	0%	0	0%	1	0%	20	56%	1326	18%	11	31%	2719	38%	30	83%	3855	54%
APR-2020	6	24%	3298	46%	5	20%	3137	43%	1	4%	35	0%	0	0%	0	0%	8	32%	1402	19%	11	44%	2637	37%	19	76%	3888	54%
MAY-2020	1	4%	3272	45%	0	0%	3111	43%	0	0%	36	0%	0	0%	0	0%	13	54%	1481	21%	11	46%	2595	36%	23	96%	3914	54%
JUN-2020	5	29%	3242	45%	5	29%	3080	43%	0	0%	33	0%	0	0%	0	0%	4	24%	1585	22%	8	47%	2517	35%	12	71%	3921	55%
JUL-2020	6	19%	3199	45%	4	13%	3039	42%	2	6%	32	0%	0	0%	0	0%	14	44%	1695	24%	12	38%	2420	34%	26	81%	3942	55%
AUG-2020	3	15%	3149	45%	2	10%	2990	42%	0	0%	31	0%	0	0%	0	0%	11	55%	1760	25%	6	30%	2313	33%	17	85%	3914	55%
SEP-2020	3	14%	3121	44%	2	10%	2960	42%	0	0%	31	0%	0	0%	0	0%	13	62%	1869	26%	5	24%	2224	32%	18	86%	3928	56%
OCT-2020	2	10%	3121	44%	2	10%	2944	41%	0	0%	29	0%	0	0%	0	0%	12	57%	1971	28%	7	33%	2135	30%	19	90%	3961	56%
NOV-2020	7	27%	3164	44%	3	12%	2934	41%	1	4%	30	0%	0	0%	0	0%	11	42%	2063	29%	8	31%	2077	29%	19	73%	3990	56%
DEC-2020	3	10%	3151	44%	3	10%	2895	40%	0	0%	29	0%	0	0%	0	0%	14	48%	2143	30%	12	41%	2020	28%	26	90%	4010	56%
JAN-2021	2	10%	3153	44%	1	5%	2880	40%	0	0%	28	0%	0	0%	0	0%	12	60%	2220	31%	6	30%	1962	27%	18	90%	4045	56%
FEB-2021	2	8%	3135	43%	2	8%	2843	39%	0	0%	27	0%	0	0%	0	0%	16	67%	2298	32%	6	25%	1899	26%	22	92%	4061	56%
MAR-2021	8	22%	3140	43%	7	19%	2832	39%	0	0%	24	0%	0	0%	0	0%	23	62%	2368	33%	6	16%	1858	26%	29	78%	4111	57%
APR-2021	2	8%	3137	43%	2	8%	2802	39%	0	0%	25	0%	0	0%	0	0%	17	68%	2422	33%	6	24%	1791	25%	23	92%	4104	57%
MAY-2021	7	24%	3150	43%	3	10%	2784	38%	0	0%	22	0%	0	0%	0	0%	15	52%	2497	34%	10	34%	1759	24%	22	76%	4131	57%
JUN-2021	4	15%	3137	43%	3	12%	2741	38%	0	0%	23	0%	0	0%	0	0%	17	65%	2574	35%	5	19%	1698	23%	22	85%	4153	57%
JUL-2021	3	15%	3126	43%	2	10%	2707	37%	0	0%	23	0%	0	0%	0	0%	13	65%	2627	36%	4	20%	1655	23%	17	85%	4167	57%
AUG-2021	1	5%	3109	43%	1	5%	2667	37%	0	0%	23	0%	0	0%	0	0%	16	73%	2665	36%	5	23%	1632	22%	21	95%	4188	57%
SEP-2021	4	13%	3082	42%	2	7%	2618	36%	1	3%	22	0%	0	0%	0	0%	21	70%	2713	37%	5	17%	1587	22%	26	87%	4184	57%
OCT-2021	5	22%	3086	42%	5	22%	2595	36%	0	0%	20	0%	0	0%	0	0%	13	57%	2758	38%	5	22%	1563	21%	18	78%	4199	58%
NOV-2021	3	12%	3072	42%	2	8%	2553	35%	0	0%	19	0%	0	0%	0	0%	18	72%	2820	39%	4	16%	1536	21%	22	88%	4226	58%
DEC-2021	3	18%	3072	42%	1	6%	2517	34%	0	0%	19	0%	0	0%	0	0%	10	59%	2870	39%	5	29%	1505	21%	14	82%	4247	58%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		saquinavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	0 0%	2 0%	0 0%	910 37%	6 86%	1466 59%	1 14%	96 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2020	0 0%	2 0%	1 11%	873 36%	8 89%	1454 60%	0 0%	96 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
MAR-2020	0 0%	2 0%	1 10%	860 36%	9 90%	1434 60%	0 0%	93 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
APR-2020	0 0%	2 0%	0 0%	838 36%	4 80%	1412 60%	1 20%	93 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
MAY-2020	0 0%	2 0%	1 10%	834 36%	9 90%	1411 60%	0 0%	89 4%	0 0%	0 0%	0 0%	6 0%	0 0%	0 0%
JUN-2020	0 0%	2 0%	2 33%	812 35%	4 67%	1386 61%	0 0%	86 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
JUL-2020	0 0%	1 0%	0 0%	779 35%	8 100%	1359 61%	0 0%	81 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
AUG-2020	0 0%	1 0%	1 20%	749 35%	4 80%	1327 62%	0 0%	79 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
SEP-2020	0 0%	0 0%	1 33%	734 35%	2 67%	1298 61%	0 0%	79 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
OCT-2020	0 0%	0 0%	0 0%	711 34%	6 100%	1281 62%	0 0%	77 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
NOV-2020	0 0%	1 0%	0 0%	694 34%	3 100%	1270 62%	0 0%	77 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
DEC-2020	0 0%	1 0%	1 8%	677 33%	11 92%	1286 63%	0 0%	76 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
JAN-2021	0 0%	1 0%	0 0%	655 32%	5 100%	1297 64%	0 0%	71 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2021	0 0%	1 0%	0 0%	643 33%	5 100%	1262 64%	0 0%	71 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
MAR-2021	0 0%	1 0%	1 25%	621 32%	3 75%	1261 65%	0 0%	73 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
APR-2021	0 0%	1 0%	0 0%	595 31%	4 100%	1230 65%	0 0%	72 4%	0 0%	1 0%	0 0%	2 0%	0 0%	1 0%
MAY-2021	0 0%	1 0%	0 0%	589 31%	4 100%	1239 65%	0 0%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUN-2021	0 0%	1 0%	0 0%	573 31%	4 80%	1221 66%	1 20%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUL-2021	0 0%	1 0%	0 0%	560 30%	6 100%	1216 66%	0 0%	68 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
AUG-2021	0 0%	0 0%	0 0%	548 30%	2 100%	1206 66%	0 0%	66 4%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
SEP-2021	0 0%	1 0%	0 0%	536 30%	2 100%	1186 67%	0 0%	61 3%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
OCT-2021	0 0%	1 0%	0 0%	516 29%	3 100%	1185 67%	0 0%	59 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
NOV-2021	0 0%	1 0%	0 0%	509 29%	3 75%	1172 68%	1 25%	58 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
DEC-2021	0 0%	1 0%	0 0%	492 29%	2 100%	1156 68%	0 0%	58 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	0 0%	1 0%	3 100%	590 36%	0 0%	202 12%	0 0%	501 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	558 36%	0 0%	198 13%	0 0%	483 31%	0 0%	320 21%
MAR-2020	0 0%	1 0%	4 100%	547 36%	0 0%	195 13%	0 0%	464 31%	0 0%	315 21%
APR-2020	0 0%	1 0%	6 86%	542 36%	0 0%	190 13%	0 0%	456 30%	1 14%	313 21%
MAY-2020	0 0%	1 0%	1 50%	536 36%	0 0%	193 13%	0 0%	452 30%	1 50%	305 21%
JUN-2020	0 0%	1 0%	2 100%	524 36%	0 0%	189 13%	0 0%	447 30%	0 0%	307 21%
JUL-2020	0 0%	3 0%	2 50%	507 35%	0 0%	184 13%	2 50%	438 31%	0 0%	305 21%
AUG-2020	1 100%	4 0%	0 0%	501 36%	0 0%	179 13%	0 0%	421 30%	0 0%	294 21%
SEP-2020	0 0%	5 0%	1 33%	476 35%	0 0%	174 13%	0 0%	409 30%	2 67%	293 22%
OCT-2020	0 0%	9 1%	1 100%	461 35%	0 0%	171 13%	0 0%	402 30%	0 0%	279 21%
NOV-2020	0 0%	10 1%	2 67%	451 35%	0 0%	171 13%	1 33%	393 30%	0 0%	279 21%
DEC-2020	0 0%	11 1%	2 67%	437 34%	0 0%	163 13%	0 0%	383 30%	1 33%	276 22%
JAN-2021	0 0%	11 1%	1 100%	426 34%	0 0%	164 13%	0 0%	379 30%	0 0%	272 22%
FEB-2021	0 0%	15 1%	0 0%	418 34%	0 0%	161 13%	0 0%	365 30%	0 0%	267 22%
MAR-2021	0 0%	21 2%	2 100%	419 34%	0 0%	162 13%	0 0%	365 30%	0 0%	266 22%
APR-2021	0 0%	20 2%	1 50%	409 34%	0 0%	155 13%	1 50%	359 30%	0 0%	260 22%
MAY-2021	1 20%	30 3%	3 60%	397 33%	0 0%	154 13%	0 0%	353 30%	1 20%	259 22%
JUN-2021	0 0%	41 4%	2 100%	379 32%	0 0%	155 13%	0 0%	345 30%	0 0%	251 22%
JUL-2021	0 0%	45 4%	1 100%	371 32%	0 0%	153 13%	0 0%	339 29%	0 0%	243 21%
AUG-2021	0 0%	56 5%	1 100%	366 32%	0 0%	150 13%	0 0%	337 29%	0 0%	241 21%
SEP-2021	0 0%	67 6%	3 75%	357 31%	0 0%	146 13%	0 0%	332 29%	1 25%	242 21%
OCT-2021	1 14%	81 7%	1 14%	350 31%	1 14%	142 12%	1 14%	326 29%	3 43%	244 21%
NOV-2021	0 0%	92 8%	1 33%	346 30%	0 0%	143 13%	0 0%	318 28%	2 67%	244 21%
DEC-2021	0 0%	99 9%	3 75%	340 30%	0 0%	135 12%	0 0%	317 28%	1 25%	243 21%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	9 50%	421 10%	7 39%	2687 62%	0 0%	707 16%	0 0%	32 1%	2 11%	594 14%
FEB-2020	14 52%	602 14%	11 41%	2642 60%	2 7%	654 15%	0 0%	29 1%	0 0%	576 13%
MAR-2020	19 68%	755 17%	7 25%	2623 58%	1 4%	623 14%	1 4%	30 1%	0 0%	562 12%
APR-2020	7 50%	827 18%	6 43%	2589 57%	1 7%	607 13%	0 0%	29 1%	0 0%	544 12%
MAY-2020	10 56%	911 20%	6 33%	2554 56%	2 11%	597 13%	0 0%	27 1%	0 0%	541 12%
JUN-2020	4 31%	1022 22%	9 69%	2537 55%	0 0%	582 13%	1 8%	28 1%	0 0%	538 12%
JUL-2020	9 38%	1140 24%	10 42%	2508 54%	5 21%	549 12%	0 0%	29 1%	0 0%	527 11%
AUG-2020	10 59%	1219 26%	6 35%	2458 52%	1 6%	518 11%	0 0%	29 1%	0 0%	520 11%
SEP-2020	13 87%	1336 28%	2 13%	2440 51%	0 0%	498 10%	0 0%	29 1%	0 0%	504 11%
OCT-2020	10 59%	1444 30%	5 29%	2424 50%	0 0%	493 10%	0 0%	30 1%	2 12%	493 10%
NOV-2020	8 36%	1540 31%	9 41%	2475 50%	2 9%	480 10%	0 0%	27 1%	3 14%	489 10%
DEC-2020	10 53%	1624 33%	7 37%	2465 49%	2 11%	458 9%	0 0%	27 1%	0 0%	477 10%
JAN-2021	12 80%	1697 34%	3 20%	2461 49%	0 0%	442 9%	0 0%	27 1%	0 0%	469 9%
FEB-2021	14 64%	1774 35%	5 23%	2476 49%	3 14%	420 8%	0 0%	24 0%	0 0%	457 9%
MAR-2021	23 72%	1839 35%	9 28%	2491 48%	0 0%	418 8%	0 0%	24 0%	0 0%	454 9%
APR-2021	15 75%	1901 36%	4 20%	2504 48%	1 5%	412 8%	0 0%	22 0%	0 0%	438 8%
MAY-2021	15 65%	1979 37%	7 30%	2509 47%	0 0%	397 7%	0 0%	22 0%	1 4%	439 8%
JUN-2021	16 76%	2056 38%	4 19%	2498 47%	1 5%	387 7%	0 0%	23 0%	0 0%	440 8%
JUL-2021	13 81%	2112 39%	3 19%	2498 46%	0 0%	382 7%	0 0%	23 0%	0 0%	432 8%
AUG-2021	15 71%	2154 40%	5 24%	2488 46%	1 5%	375 7%	0 0%	23 0%	0 0%	424 8%
SEP-2021	18 72%	2198 40%	5 20%	2473 46%	2 8%	366 7%	0 0%	23 0%	0 0%	411 8%
OCT-2021	11 73%	2238 41%	3 20%	2472 45%	1 7%	362 7%	0 0%	24 0%	0 0%	398 7%
NOV-2021	17 77%	2312 42%	4 18%	2461 45%	1 5%	347 6%	0 0%	24 0%	0 0%	392 7%
DEC-2021	8 57%	2358 43%	5 36%	2467 45%	1 7%	348 6%	0 0%	24 0%	0 0%	381 7%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2020	1617	21.98	1210	16.44	3562	48.41	55	0.75	761	10.34	153	2.08
FEB-2020	1573	21.46	1154	15.75	3643	49.71	55	0.75	757	10.33	147	2.01
MAR-2020	1540	20.85	1134	15.35	3755	50.83	57	0.77	759	10.27	142	1.92
APR-2020	1522	20.55	1129	15.24	3807	51.39	57	0.77	750	10.12	143	1.93
MAY-2020	1512	20.44	1111	15.02	3830	51.78	56	0.76	748	10.11	140	1.89
JUN-2020	1458	19.79	1084	14.71	3881	52.67	55	0.75	752	10.21	138	1.87
JUL-2020	1420	19.36	1058	14.43	3935	53.66	57	0.78	729	9.94	134	1.83
AUG-2020	1375	18.95	1026	14.14	3944	54.36	66	0.91	714	9.84	130	1.79
SEP-2020	1336	18.47	980	13.55	3999	55.28	79	1.09	710	9.81	130	1.80
OCT-2020	1308	18.00	964	13.27	4058	55.86	101	1.39	701	9.65	133	1.83
NOV-2020	1287	17.53	946	12.89	4128	56.24	159	2.17	697	9.50	123	1.68
DEC-2020	1272	17.32	924	12.58	4152	56.52	177	2.41	703	9.57	118	1.61
JAN-2021	1273	17.24	912	12.35	4191	56.76	202	2.74	693	9.39	113	1.53
FEB-2021	1232	16.70	894	12.12	4226	57.29	223	3.02	689	9.34	113	1.53
MAR-2021	1209	16.27	890	11.98	4274	57.51	246	3.31	707	9.51	106	1.43
APR-2021	1166	15.72	868	11.70	4319	58.23	273	3.68	690	9.30	101	1.36
MAY-2021	1146	15.38	858	11.51	4348	58.35	296	3.97	704	9.45	100	1.34
JUN-2021	1125	15.09	834	11.19	4370	58.61	324	4.35	705	9.46	98	1.31
JUL-2021	1104	14.80	820	10.99	4384	58.76	352	4.72	702	9.41	99	1.33
AUG-2021	1091	14.60	817	10.94	4388	58.73	377	5.05	701	9.38	97	1.30
SEP-2021	1071	14.39	812	10.91	4378	58.83	394	5.29	695	9.34	92	1.24
OCT-2021	1054	14.17	809	10.88	4391	59.03	406	5.46	687	9.24	92	1.24
NOV-2021	1038	13.92	804	10.78	4405	59.07	435	5.83	684	9.17	91	1.22
DEC-2021	1020	13.64	792	10.59	4425	59.18	464	6.21	686	9.17	90	1.20

**Definitions:**

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	23	4	0	3	1	10	550
APR-2020	8	0	0	3	0	5	686
MAY-2020	15	1	0	3	4	7	400
JUN-2020	9	1	0	3	4	1	380
JUL-2020	12	3	0	0	2	4	500
AUG-2020	11	3	1	3	2	1	225
SEP-2020	8	3	2	1	0	0	71
OCT-2020	13	2	1	1	3	3	381
NOV-2020	11	0	1	0	2	6	710
DEC-2020	13	3	3	3	0	4	260
JAN-2021	9	1	3	0	1	2	170
FEB-2021	13	0	2	3	4	4	360
MAR-2021	24	4	5	3	5	5	280
APR-2021	9	2	1	1	1	4	370
MAY-2021	14	1	1	3	2	4	480
JUN-2021	15	4	1	3	2	4	289
JUL-2021	12	1	2	0	2	4	480
AUG-2021	12	1	1	4	2	2	300
SEP-2021	9	0	1	2	2	3	400
OCT-2021	6	1	0	1	0	2	490
NOV-2021	15	3	2	2	2	3	260
DEC-2021	6	1	1	1	3	0	350

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2020	12525	4021
FEB-2020	12557	4039
MAR-2020	12558	4030
APR-2020	12536	4006
MAY-2020	12526	3994
JUN-2020	12503	3972
JUL-2020	12480	3939
AUG-2020	12448	3915
SEP-2020	12411	3887
OCT-2020	12389	3875
NOV-2020	12403	3876
DEC-2020	12380	3837
JAN-2021	12389	3839
FEB-2021	12381	3833
MAR-2021	12379	3822
APR-2021	12368	3809
MAY-2021	12363	3797
JUN-2021	12364	3791
JUL-2021	12385	3810
AUG-2021	12379	3816
SEP-2021	12348	3784
OCT-2021	12336	3776
NOV-2021	12339	3767
DEC-2021	12324	3763

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved  
**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month









3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7477  
Dec-2021

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY









3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Dec-2021

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Dec-2021

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Dec-2021

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Dec-2021

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Dec-2021

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	8	8	*
	35-49	10	11	*
	50+	29	41	*
	<b>Total HSDA:</b>	<b>47</b>	<b>60</b>	<b>29</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>73</b>	<b>100</b>	<b>57</b>
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>411</b>	<b>553</b>	<b>317</b>
THOMPSON/CARIBOO/ SHUSWAP	20-34	21	21	13
	35-49	68	74	43
	50+	119	191	95
	<b>Total HSDA:</b>	<b>208</b>	<b>286</b>	<b>151</b>
<b>Total HA:</b>		<b>739</b>	<b>999</b>	<b>554</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>739</b>	<b>999</b>	<b>554</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	144	198	106
Male	595	801	448

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	554	56	620	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





### 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	24	14
	5 years or more	13	9
	<5 years	10	6
	<b>Total HSDA:</b>	<b>47</b>	<b>29</b>
KOOTENAY BOUNDARY	10 years or more	46	35
	5 years or more	15	10
	<5 years	12	12
	<b>Total HSDA:</b>	<b>73</b>	<b>57</b>
OKANAGAN	10 years or more	266	198
	5 years or more	91	76
	<5 years	54	43
	<b>Total HSDA:</b>	<b>411</b>	<b>317</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	132	99
	5 years or more	46	31
	<5 years	30	21
	<b>Total HSDA:</b>	<b>208</b>	<b>151</b>
<b>Total HA:</b>		<b>739</b>	<b>554</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	468	346
	5 years or more	165	126
	<5 years	106	82
<b>Total HA:</b>		<b>739</b>	<b>554</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	51	70	13	28
KOOTENAY BOUNDARY	77	132	26	53
OKANAGAN	232	980	51	298
THOMPSON/CARIBOO/SHUSWAP	142	538	36	136
<b>Total:</b>	<b>502</b>	<b>1720</b>	<b>126</b>	<b>515</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
<b>Total:</b>	<b>114</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA







#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	33	35	27
	35-49	94	100	60
	50+	242	337	184
	<b>Total HSDA:</b>	<b>375</b>	<b>478</b>	<b>277</b>
FRASER NORTH	20-34	122	122	82
	35-49	347	373	260
	50+	627	989	482
	<b>Total HSDA:</b>	<b>1096</b>	<b>1484</b>	<b>824</b>
FRASER SOUTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>1019</b>	<b>1349</b>	<b>812</b>
<b>Total HA:</b>		<b>2490</b>	<b>3311</b>	<b>1913</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	9
	20-34	266	270	184
	35-49	744	809	560
	50+	1470	2222	1160
<b>Total HA:</b>		<b>2490</b>	<b>3311</b>	<b>1913</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	603	771	444
Male	1887	2540	1469

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1913	53	649	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	232	173
	5 years or more	80	55
	<5 years	63	49
	<b>Total HSDA:</b>	<b>375</b>	<b>277</b>
FRASER NORTH	10 years or more	675	484
	5 years or more	234	187
	<5 years	187	153
	<b>Total HSDA:</b>	<b>1096</b>	<b>824</b>
FRASER SOUTH	10 years or more	616	485
	5 years or more	232	182
	<5 years	171	145
	<b>Total HSDA:</b>	<b>1019</b>	<b>812</b>
<b>Total HA:</b>		<b>2490</b>	<b>1913</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1523	1142
	5 years or more	546	424
	<5 years	421	347
<b>Total HA:</b>		<b>2490</b>	<b>1913</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	141	513	31	57
FRASER NORTH	256	1620	44	216
FRASER SOUTH	225	1665	54	481
<b>Total:</b>	<b>622</b>	<b>3798</b>	<b>129</b>	<b>754</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	184
FRASER NORTH	686
FRASER SOUTH	455
<b>Total:</b>	<b>1325</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>352</b>	<b>511</b>
RICHMOND	20-34	32	33	17
	35-49	47	49	39
	50+	110	161	91
	<b>Total HSDA:</b>	<b>189</b>	<b>243</b>	<b>147</b>
VANCOUVER	0-19	11	11	10
	20-34	431	450	282
	35-49	1274	1424	918
	50+	2929	5136	2130
	<b>Total HSDA:</b>	<b>4645</b>	<b>7021</b>	<b>3340</b>
<b>Total HA:</b>		<b>5186</b>	<b>7775</b>	<b>3774</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	11
	20-34	493	513	321
	35-49	1405	1565	1018
	50+	3276	5685	2424
<b>Total HA:</b>		<b>5186</b>	<b>7775</b>	<b>3774</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	605	954	450
Male	4579	6819	3324
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3774	55	650	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	215	174
	5 years or more	76	64
	<5 years	61	49
	<b>Total HSDA:</b>	<b>352</b>	<b>287</b>
RICHMOND	10 years or more	112	87
	5 years or more	33	24
	<5 years	44	36
	<b>Total HSDA:</b>	<b>189</b>	<b>147</b>
VANCOUVER	10 years or more	3104	2164
	5 years or more	922	688
	<5 years	619	488
	<b>Total HSDA:</b>	<b>4645</b>	<b>3340</b>
<b>Total HA:</b>		<b>5186</b>	<b>3774</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3431	2425
	5 years or more	1031	776
	<5 years	724	573
<b>Total HA:</b>		<b>5186</b>	<b>3774</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	183	410	55	80
RICHMOND	43	297	7	90
VANCOUVER	657	11234	215	5351
<b>Total:</b>	<b>883</b>	<b>11941</b>	<b>277</b>	<b>5521</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
<b>Total:</b>	<b>75</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>340</b>	<b>495</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>121</b>	<b>169</b>
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>781</b>	<b>1113</b>
<b>Total HA:</b>		<b>1242</b>	<b>1777</b>	<b>967</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	5
	20-34	115	125	75
	35-49	290	335	233
	50+	831	1311	654
<b>Total HA:</b>		<b>1242</b>	<b>1777</b>	<b>967</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	216	312	169
Male	1026	1465	798

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	967	55	590	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	204	165
	5 years or more	80	61
	<5 years	56	43
	<b>Total HSDA:</b>	<b>340</b>	<b>269</b>
NORTH VANCOUVER ISLAND	10 years or more	80	68
	5 years or more	29	18
	<5 years	12	11
	<b>Total HSDA:</b>	<b>121</b>	<b>97</b>
SOUTH VANCOUVER ISLAND	10 years or more	468	334
	5 years or more	159	132
	<5 years	154	135
	<b>Total HSDA:</b>	<b>781</b>	<b>601</b>
<b>Total HA:</b>		<b>1242</b>	<b>967</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	752	567
	5 years or more	268	211
	<5 years	222	189
<b>Total HA:</b>		<b>1242</b>	<b>967</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation







**4.12 Distribution of ARV Prescribers in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	203	905	72	196
NORTH VANCOUVER ISLAND	153	274	45	73
SOUTH VANCOUVER ISLAND	220	1882	43	575
<b>Total:</b>	<b>576</b>	<b>3061</b>	<b>160</b>	<b>844</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	58
NORTH VANCOUVER ISLAND	41
SOUTH VANCOUVER ISLAND	131
<b>Total:</b>	<b>230</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





### 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>46</b>	<b>57</b>	<b>23</b>
NORTH WEST	20-34	*	6	0
	35-49	*	40	20
	50+	*	72	36
	<b>Total HSDA:</b>	<b>71</b>	<b>118</b>	<b>56</b>
NORTHERN INTERIOR	0-19	6	6	*
	20-34	22	24	*
	35-49	55	70	*
	50+	110	184	*
	<b>Total HSDA:</b>	<b>193</b>	<b>284</b>	<b>142</b>
<b>Total HA:</b>		<b>310</b>	<b>459</b>	<b>221</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	30	34	*
	35-49	99	132	*
	50+	175	287	*
<b>Total HA:</b>		<b>310</b>	<b>459</b>	<b>221</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	116	172	81
Male	194	287	140

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	221	52	560	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	29	*
	5 years or more	6	*
	<5 years	11	*
	<b>Total HSDA:</b>	<b>46</b>	<b>23</b>
NORTH WEST	10 years or more	45	34
	5 years or more	14	12
	<5 years	12	10
	<b>Total HSDA:</b>	<b>71</b>	<b>56</b>
NORTHERN INTERIOR	10 years or more	96	74
	5 years or more	61	41
	<5 years	36	27
	<b>Total HSDA:</b>	<b>193</b>	<b>142</b>
<b>Total HA:</b>		<b>310</b>	<b>221</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	170	121
5 years or more	81	55
<5 years	59	45
<b>Total HA:</b>	<b>310</b>	<b>221</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	39	61	4	*
NORTH WEST	82	167	17	*
NORTHERN INTERIOR	118	483	21	*
<b>Total:</b>	<b>239</b>	<b>711</b>	<b>42</b>	<b>230</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	6
NORTH WEST	22
NORTHERN INTERIOR	13
<b>Total:</b>	<b>41</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth**

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	7	11	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	27	44	18
	THOMPSON/CARIBOO/SHUSWAP	26	50	18
	<b>Total HA:</b>	<b>66</b>	<b>114</b>	<b>47</b>
FRASER	FRASER EAST	33	46	25
	FRASER NORTH	53	92	41
	FRASER SOUTH	84	118	60
	<b>Total HA:</b>	<b>170</b>	<b>256</b>	<b>126</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	28	51	24
	RICHMOND	8	13	6
	VANCOUVER	466	891	372
	<b>Total HA:</b>	<b>502</b>	<b>955</b>	<b>402</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	47	81	37
	NORTH VANCOUVER ISLAND	13	25	12
	SOUTH VANCOUVER ISLAND	45	89	37
	<b>Total HA:</b>	<b>105</b>	<b>195</b>	<b>86</b>
NORTHERN	NORTH EAST	11	15	6
	NORTH WEST	31	66	25
	NORTHERN INTERIOR	68	111	56
	<b>Total HA:</b>	<b>110</b>	<b>192</b>	<b>87</b>
<b>Total:</b>		<b>953</b>	<b>1712</b>	<b>748</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	605	1100	470
Female	348	612	278

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	748	53	520	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Bictegravir:** an INTEGRASE INHIBITOR from Gilead Sciences.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicistat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

**Complera (CPL):** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





**Descovy (DSC):** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay, DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare.

**Doravirine:** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

**Efavirenz (Sustiva, Auro efavirenz, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine (FTC):** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intelence, ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya (GNV):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.







## Monthly Report

**Maraviroc (Celsentri, MVC):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**N(t)RTI:** a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**Odefsey (ODF):** the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.







## Monthly Report

**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix (PZC):** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant, RPV):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq (TRQ):** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir (TRZ):** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada (TRU):** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





## Monthly Report

---

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

